RNAC — Cartesian Therapeutics Share News
0.000.00%
Last trade - 00:00- $186.98m
- $92.22m
- $2.80m
Brief: Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Descartes-08 For The Treatment Of Myasthenia Gravis
Cartesian Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview
Brief: Cartesian Therapeutics Regains Compliance With $1 Per Share Minimum Bid Price Requirement For Continued Inclusion On Nasdaq
Cartesian Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cartesian Therapeutics Says Topline Data From Phase 2B Study Of Descartes-08 In Myasthenia Gravis (Mg) Is Expected In Mid-2024
Cartesian Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Cartesian Therapeutics Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Cartesian Therapeutics' Cash & Cash Equivalents Expected To Support Planned Operations Into 2026
U.S. STOCKS ON THE MOVE-Boeing, Booking Holdings, Eli Lilly
Selecta Biosciences falls on merger with privately held Cartesian Therapeutics
Brief: Selecta Biosciences Announces Merger With Cartesian Therapeutics
Brief: Selecta Announces Transition Of Manufacturing And Clinical Operations Of Immtor For Sel-212 To Commercialization Partner SOBI
Selecta Biosciences Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Selecta Biosciences Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
U.S. RESEARCH ROUNDUP-Applied Materials, Walmart, Zscaler
U.S. STOCKS ON THE MOVE-Canopy Growth, Teck Resources, Chegg
U.S. STOCKS ON THE MOVE-Copper miners, US energy firms, CVS Health
Selecta Biosciences falls on Q2 revenue miss
Selecta Biosciences Inc reports results for the quarter ended in June - Earnings Summary